Jacob Brogren(1) Svante Nyberg(2) Transit Compartment Model Useful for Describing Absorption of Quetiapine XR and IR
|
Monica Simeoni1, Michael Gold2, Marina Zvartau-Hind3, Michael Irizarry4, Daren Austin1, Roberto Gomeni5 Clinical and Genetic factors affecting Alzheimer’s disease progression in subjects on stable acetylcholinesterase inhibitor therapy: a comparison between mechanistic and empirical disease progression modelling approaches
|
Gai Ling Li, Don Nichols Towards Quantitative Prediction Of In Vivo Brain Penetration Using A Physiology Based CNS Disposition Model
|
Monica Simeoni(1), Michael Gold(2), Marina Zvartau-Hind(3), Michael Irizarry(4), Daren Austin(1), Roberto Gomeni(5) Disease System Analysis: Evaluate the structural properties and the physiological implications of an indirect physiologic response model describing the degenerative progression of Alzheimer’s disease using a closed-form solution
|
Marcel PH van den Broek (1), Alwin DR Huitema (2), Floris Groenendaal (3), Antoine CG Egberts (1,4), Carin MA Rademaker (1), Linda S de Vries (3) Optimal dosing of lidocaine for seizure control in preterm and term neonates using population pharmacokinetic modelling and simulation
|
M.A. Björnsson(1,2), U.S.H. Simonsson(2) Modeling of Pain Intensity Measured on a Visual Analogue Scale and Informative Dropout in a Dental Pain Model after Naproxcinod and Naproxen Administration
|
E. Yuen(1,2), I. Gueorguieva(1), L. Aarons(2) A population pharmacokinetic/pharmacodynamic model for duloxetine in diabetic peripheral neuropathy, plus methods for handling missing data.
|
Rik Schoemaker(1), Eric Snoeck(1), Armel Stockis(2) Exposure-response modeling of daily seizure counts in focal epilepsy trials
|
Y. Chiu(1), J. Nielsen(2), D. Sarrubi(1), K. Kowalski(2) Population Pharmacokinetics of Lurasidone in Healthy Subjects and Subjects with Schizophrenia
|
M. Kågedal(1), Z. Cseleny(1), S. Nyberg(1), Per Karlsson (2), A Hooker(3), MO Karlsson(3) Estimation of occupancy and radioligand kinetics in the CNS from PET-data in the absence of a reference region.
|
Neil J Attkins(1), Simeon Ramsey(2), Rebecca Fish(2), Piet H. van der Graaf(1) Model based analysis of antagonist binding kinetics at CRF-1 receptors in vitro and in vivo
|
Venkatesh Pilla Reddy*(1), Magdalena Kozielska(1), Martin Johnson(1), An Vermeulen(2), Rik de Greef(3), Jing Liu(4), Geny M.M. Groothuis(5), Meindert Danhof(6) and Johannes H. Proost(1) Modeling and Simulation of Placebo Response and Dropout Patterns in Treatment of Schizophrenia
|
P. Välitalo[1], E. Kumpulainen[1], M. Manner [1], M. Laisalmi[2], M. Lehtonen[1], A. Hooker[3], V-P. Ranta[1], H. Kokki[2] Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children
|
Martin Johnson[1], Magdalena Kozielska[1], Venkatesh Pilla Reddy[1], An Vermeulen[2], Rik de Greef[3], Cheryl Li[4], Sarah Grimwood[4], Jing Liu[4], Geny M. M. Groothuis[1], Meindert Danhof[5] and Johannes H. Proost[1] Evaluation of a Mechanism-Based Pharmacokinetic-Pharmacodynamic Model for D2 Receptor Occupancy of Olanzapine in Rats
|
Magdalena Kozielska (1), Martin Johnson (1), Venkatesh Pilla Reddy (1), An Vermeulen (2), Rik de Greef (3), Cheryl Li (4), Sarah Grimwood (4), Jing Liu (4), Geny M. M. Groothuis (1), Meindert Danhof (5), Johannes H. Proost (1) Predictive performance of two PK-PD models of D2 receptor occupancy of the antipsychotics risperidone and paliperidone in rats
|
M. Campioni (1), S. Krösser (1), M.M. Thapar (2)*, S.C. Hayes (2), E. Gibiansky (3), V. Lucini (4), R. Anand (5), *Presenting author Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease
|
Mahesh N. Samtani (1); Srihari Gopal (1); Jennifer Kern Sliwa (2); J. Thomas Haskins (2); Larry Alphs (2); Kim Stuyckens (3); An Vermeulen (3). Switching to Paliperidone Palmitate[1,2] from Other Depot Antipsychotics: Guidance Based on Pharmacokinetic Simulations
|
Kristin E. Karlsson (1), Mats O. Karlsson (1) and E. Niclas Jonsson (1)(2) Clinical trial simulations using a stroke disease progression model
|
Gordon Graham, Francois, Mercier, Mick Looby Amy Racine Continuous time Markov modelling of relapse sojourns for relapse-remitting multiple sclerosis patients
|
Zamuner S. (1), Paronetto M. (1), Moscardo E. (2), Renzulli C. (3), Terron A. (2), Poggesi I. (1) The assessment of convulsion risk: a translational PK/PD modelling approach
|
Andrew C. Hooker (1), Elizabeth Dunn-Sims (3), David Fairman (2), Andy Mead (3), Piet Van Der Graaf (2) and Mats O. Karlsson (1) Title: Modeling exposure-response relationships in the rat self-administration model
|
V.L. Di Iorio(1), R. Clinckers(1,2), I. Smolders(2), Y. Michotte(2), E.C. de Lange(1), M. Danhof(1), R.A. Voskuyl(1), O. Della Pasqua(1) Impact of Seizures and Efflux Mechanisms on the Biophase Kinetics and CNS Effects of Anticonvulsant Drugs
|
Anders Viberg (1), John Martino (2), Etienne Lessard (2) and Jennifer Laird (2) Using an Innovative Design in Behavioural Pharmacology Studies Saves Money and Animal Lives
|
SeungHwan Lee, MD, Bo-Hyung Kim, MD, Donghoon Shin, MD, Min Kyu Park, MD, Sang-Goo Shin, MD, PhD, Kyung-Sang Yu, MD, PhD, In-Jin Jang, MD, PhD A population analysis of Intravenous Dexmedetomidine in Korean
|